NASDAQ:CTSO

Cytosorbents (CTSO) Stock Price, News & Analysis

Cytosorbents logo
$5.57 +1.05 (+23.23%)
Closing price 11/18/2026 03:55 PM Eastern
Extended Trading
$5.35 -0.22 (-3.95%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cytosorbents Stock (NASDAQ:CTSO)

Advanced

Key Stats

Today's Range
$4.37
▼
$5.75
50-Day Range
$3.06
▼
$6.41
52-Week Range
$2.84
▼
$17.00
Volume
13,891 shs
Average Volume
29,099 shs
Market Capitalization
$17.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$104.75
Consensus Rating
Hold

Company Overview

Cytosorbents Corp. develops blood-purification technologies for use in hospitals and other clinical settings. Its products are designed to work with extracorporeal circuits, where blood is circulated outside the body and passed through a purification device.

The company’s best-known product, CytoSorb, is an adsorber intended to remove certain inflammatory substances and other compounds from blood. It is used in areas such as critical care and cardiac surgery. Cytosorbents also develops DrugSorb-ATR, a device designed to remove certain blood-thinning drugs during cardiac procedures.

Founded as MedaSorb Technologies in 1997, the company adopted the Cytosorbents name in 2006 and is based in Princeton, New Jersey. Its products are distributed internationally, with use in Europe and other markets. Phillip Chan serves as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Cytosorbents Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

CTSO MarketRank™: 
3.47680306555 of 5 stars

Cytosorbents scored higher than 70% of companies evaluated by MarketBeat, and ranked 387th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytosorbents has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Cytosorbents has a consensus price target of $104.75, representing about 1,780.6% upside from its current price of $5.57.

  • Amount of Analyst Coverage

    Cytosorbents has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cytosorbents' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytosorbents are expected to grow in the coming year, from ($4.40) to ($0.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytosorbents is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytosorbents is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytosorbents has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.64% of the float of Cytosorbents has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytosorbents has a short interest ratio ("days to cover") of 1.11, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cytosorbents has recently increased by 17.91%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cytosorbents does not currently pay a dividend.

  • Dividend Growth

    Cytosorbents does not have a long track record of dividend growth.

  • News Sentiment

    Cytosorbents has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Cytosorbents this week, compared to 2 articles on an average week.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $92,644.00 in company stock, which represents 0.5280% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $92,644.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    7.80% of the stock of Cytosorbents is held by insiders.

  • Percentage Held by Institutions

    32.87% of the stock of Cytosorbents is held by institutions.

  • Read more about Cytosorbents' insider trading history.
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTSO Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Cytosorbents (CTSO) AI Stock Analysis
Cytosorbents (CTSO) Q3 2026 Earnings Call Transcript
See More Headlines

CTSO Stock Analysis - Frequently Asked Questions

Cytosorbents' stock was trading at $12.7840 at the beginning of the year. Since then, CTSO stock has decreased by 56.4% and is now trading at $5.57.

Cytosorbents Corporation (NASDAQ:CTSO) released its quarterly earnings data on Thursday, November, 12th. The medical research company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.32. The medical research company earned $9.73 million during the quarter, compared to analysts' expectations of $9.90 million. Cytosorbents had a negative trailing twelve-month return on equity of 689.23% and a negative net margin of 45.06%.
Read the conference call transcript
.

Cytosorbents shares reverse split on Tuesday, September 8th 2026.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 7th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cytosorbents' top institutional shareholders include Avenir Corp (8.23%). Insiders that own company stock include Phillip P Chan, Peter J Mariani and Alan D Sobel.
View institutional ownership trends
.

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Eyepoint Pharmaceuticals (EYPT).

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:CTSO
CIK
1175151
Employees
129
Year Founded
2002

Price Target and Rating

High Price Target
$200.00
Low Price Target
$9.50
Potential Upside/Downside
+1,780.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.20 million
Net Margins
-45.06%
Pretax Margin
-50.01%
Return on Equity
-689.23%
Return on Assets
-41.26%

Debt

Debt-to-Equity Ratio
4.70
Current Ratio
0.66
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$37.06 million
Price / Sales
0.47
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.88 per share
Price / Book
2.96

Miscellaneous

Outstanding Shares
3,150,000
Free Float
2,905,000
Market Cap
$17.55 million
Optionable
Optionable
Beta
1.49

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:CTSO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners